Researchers at the University of Sydney found that melatonin, a common sleep supplement, provides pain relief comparable to conventional painkillers [1].
This discovery could offer a new alternative for the millions of Australians who suffer from chronic pain [1]. By identifying a non-traditional pathway for pain management, the study suggests a way to reduce reliance on standard pharmaceutical painkillers that often carry significant side effects.
The University of Sydney team said the supplement works by directly targeting inflammatory pathways [1]. This process helps in reducing pain sensitisation, a condition where the nervous system becomes hyper-responsive to pain signals [1].
While melatonin is widely known for its role in regulating sleep-wake cycles, this research highlights its potential as a therapeutic agent for chronic conditions [2]. The study indicates that the supplement's ability to modulate inflammation allows it to function as an effective tool for pain relief [1].
The findings suggest that the supplement does not merely treat the symptoms of sleeplessness often associated with pain, but addresses the underlying inflammatory mechanisms [1]. This dual action could potentially simplify treatment regimens for patients dealing with both chronic pain and insomnia [2].
The research was conducted at the University of Sydney in Australia [1]. The team focused on how the supplement interacts with the body's biological response to injury and long-term inflammation [1].
“Melatonin provides pain relief comparable to conventional painkillers.”
If validated through broader clinical application, using melatonin for pain management could shift the treatment paradigm for chronic inflammation. By targeting pain sensitisation rather than just blocking pain receptors, this approach may provide a safer, long-term alternative to opioids or high-dose NSAIDs, particularly for patients who already use sleep aids.
